Today: 6 February 2026
Subscribe
Browse Category

NASDAQ:INO News 7 December 2025

INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

Published: December 7, 2025 Inovio Pharmaceuticals (NASDAQ: INO) has quietly turned 2025 into a make‑or‑break year. The small‑cap biotech has completed a Biologics License Application (BLA) for its lead DNA immunotherapy INO‑3107, raised fresh capital through two stock offerings, and attracted a flurry of new analyst ratings and algorithmic “Strong Buy” labels — all while still burning cash and generating…
7 December 2025
·····

Stock Market Today

  • Rexel S.A. (RXL.PA) Trades at €37.58 Pre-Earnings with Key Metrics in Focus
    February 6, 2026, 1:53 PM EST. Rexel S.A. stock (RXL.PA) trades at €37.58 after hours ahead of earnings due on Feb 11, 2026. Investors eye operating margin (~3.99%), EPS (€0.83), and revenue per share (€65.66). The firm holds a high PE ratio of 45.19, reflecting elevated expectations. Meyka AI assigns a B+ rating (73.58/100) and technical indicators show a neutral trend. The company's leverage is notable with net debt to EBITDA at 3.7, raising balance sheet scrutiny. Risks include margin pressure and weak industrial demand from last year's negative EPS growth. Meyka AI projects a near-term price dip but suggests a longer-term upside of nearly 10%. Rexel's dividend yield is 3.2%, and cash flow generation remains steady. Market focus will be on margin recovery and free cash flow guidance during the earnings release.
Go toTop